Skip to content

13F-HR filed by Octagon Capital Advisors LP

Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-15, with 34 holding rows worth $516,795,482.

Accession
0001839435-25-000004
Filed
2025-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2025

A holdings report, 35 entries on the cover page, a total value of $516,795,482 stated on the cover page (in dollars after the unit check, H1), rows summing to $516,795,482 with VALUE read as dollars as filed, 13F file number 028-20958. A later restatement replaced it, so the quarter does not use it. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SYNDAX PHARMACEUTICALS INC87164F105COM27,330,800$48,102,208dollars as filed
COGENT BIOSCIENCES INC19240Q201COM2,094,000$45,795,780dollars as filed
MAZE THERAPEUTICS INC COM578784100Stock2,341,667$42,477,839dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM2,059,387$38,078,066dollars as filed
Tourmaline Bio Inc89157D105Common Stock4,091,815$32,981,476dollars as filed
GOSSAMER BIO INC COM38341P102Stock1,425,000$20,491,500dollars as filed
MIND MEDICINE MINDMED INC60255C885COM NEW18,350,000$20,185,000dollars as filed
TAYSHA GENE THERAPIES INC877619106COMMON STOCK2,425,000$17,775,250dollars as filed
PERSPECTIVE THERAPEUTICS INC46489V302COMMON STOCK3,018,000$17,655,300dollars as filed
KALARIS THERAPEUTICS INC482929106COM2,763,000$16,550,370dollars as filed
NEUROGENE INC64135M105COMMON STOCK1,370,000$15,809,800dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock10,700,000$14,873,000dollars as filed
SCHOLAR ROCK HLDG CORP80706P103COM7,900,000$13,904,000dollars as filed
HUMACYTE INC44486Q103COM217,264$13,794,091dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM905,000$13,765,050dollars as filed
PHARVARIS NVN69605108COMMON STOCK308,000$12,963,720dollars as filed
OCULAR THERAPEUTIX INC67576A100COM296,000$11,564,720dollars as filed
UNICYCIVE THERAPEUTICS INC90466Y103CMN904,000$11,105,640dollars as filed
CORBUS PHARMACEUTICALS21833P301COM NEW3,552,000$10,727,040dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS329,000$10,577,350dollars as filed
IMMUNITYBIO INC45256X103COM1,720,000$10,371,600dollars as filed
HELIX ACQUISITION CORP IIG4444H101CL A ORD SHS600,000$8,628,000dollars as filedput
TREVI THERAPEUTICS INC COM89532M101Stock4,637,076$8,114,883dollars as filed
VERASTEM INC92337C203COMMON STOCK625,000$7,862,500dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS1,230,000$7,687,500dollars as filed
MERUS N VN5749R100COM5,136,795$7,037,409dollars as filed
CAPRICOR THERAPEUTICS INC14070B309COMMON STOCK450,000$6,066,000dollars as filed
KALVISTA PHARMACEUTICALS INC483497103COM1,115,000$5,920,650dollars as filed
ATYR PHARMA INC002120202COM NEW10,000,000$5,749,000dollars as filed
NUVATION BIO INC67080N119WARR468,000$5,152,680dollars as filed
ERASCA INC COM29479A108Stock2,250,000$4,792,500dollars as filed
NUVATION BIO INC COM CL A67080N101Stock481,000$3,862,430dollars as filed
REGULUS THERAPEUTICS INC75915K309COM303,000$3,548,130dollars as filed
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock250,000$2,825,000dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001839435-25-000004this filing2025-05-15acceptance time not in the bulk data set
13F-HR/A 0001839435-25-000005 base2025-05-16acceptance time not in the bulk data set